Business Wire

FDA Approves Biex Test to Aid in Identifying Risk of Preterm Labor and Delivery.

Business Wire | May 5, 1998 | Copyright

DUBLIN, Calif.--(BW HealthWire)--May 5, 1998--Biex, Inc. announced today the FDA granted marketing approval for the Company's salivary estriol test to help physicians identify risk for spontaneous preterm labor and delivery.

The SalEst(TM) system is approved for use in women between their 22nd and 36th week of pregnancy.

The proprietary SalEst system measures levels of the hormone, estriol, in saliva. Clinical research demonstrates that there is a surge in salivary estriol several weeks prior to the onset of spontaneous preterm labor and that salivary…

Read the rest of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

FDA Approves Biex Test to Aid in Identifying Risk of Preterm Labor and Delivery.
Business Wire ...1998--Biex, Inc. announced today the FDA granted marketing...salivary estriol test to help physicians identify risk for spontaneous preterm labor and delivery. The SalEst...marketed by Biex, Inc...With the FDA approval...

For more facts and information, see all results

Find more facts and information related to the article FDA Approves Biex Test to Aid in Identifying Risk ...